Agendia Publishes Unprecedented Full Genome Dataset from MINDACT Trial for the Advancement of Translational Research in Communications Biology
PRESS RELEASE Irvine, California., July 27, 2020 โย Agendia, Inc., a Read More
General Standby Statement
Agendia, Inc. has entered into a Settlement Agreement with the Read More
Agendia Announces Data Presented at ASCO 2020 Demonstrating Importance of Further Classification of Breast Cancers to Enable Precise Prognosis and Treatment
PRESS RELEASE Presentations outline how BluePrintโยฎโ genomic testing enables further Read More
Long-term Follow Up Data from Groundbreaking MINDACT Study Continues to Demonstrate Clinical Utility of MammaPrint
PRESS RELEASE Median follow up nearing 9 years confirms MINDACT Read More
Agendia to Showcase New Data at ASCO 2020 That Further Stratifies Breast Cancer Patients for More Precise Therapy Recommendations
PRESS RELEASE Data adds to the growing body of evidence Read More
Agendia Co-Founder and Chief Scientific Officer Renรฉ Bernards, PhD Elected to the National Academy of Sciences
PRESS RELEASE Development of MammaPrintยฎ, first FDA-cleared molecular diagnostic test Read More
Long Term Analytical Validation Study Further Confirms BluePrint as a Reliable Genomic Profiling Assay for Early Stage Breast Cancer Patients
PRESS RELEASE ย IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ Read More
Agendia COVID-19 Statement
As a valued customer we wanted to reach out and Read More
Results from the IMPACt Trial Show Agendia Assays Consistently Inform Treatment Planning and Increase Physician Confidence when Caring for Patients with Early Stage Breast Cancer
PRESS RELEASE Laura van โt Veer, PhD, Co-Inventor of MammaPrint, Read More
Laura van โt Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020
PRESS RELEASE Laura van โt Veer, PhD, Co-Inventor of MammaPrint, Read More
